European journal of gynaecological oncology (EUR J GYNAECOL ONCOL)

Current impact factor: 0.61

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 0.611
2013 Impact Factor 0.602
2012 Impact Factor 0.577
2011 Impact Factor 0.474
2010 Impact Factor 0.633
2009 Impact Factor 0.614
2008 Impact Factor 0.641
2007 Impact Factor 0.587
2006 Impact Factor 0.652
2005 Impact Factor 0.591
2004 Impact Factor 0.509
2003 Impact Factor 0.547
2002 Impact Factor 0.395
2001 Impact Factor 0.562
2000 Impact Factor 0.551
1999 Impact Factor 0.397

Impact factor over time

Impact factor

Additional details

5-year impact 0.60
Cited half-life 7.30
Immediacy index 0.05
Eigenfactor 0.00
Article influence 0.14
Website European Journal of Gynaecological Oncology website
Other titles European journal of gynaecological oncology
ISSN 0392-2936
OCLC 7236962
Material type Periodical
Document type Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Growing teratoma syndrome (GTS) is a rare condition among patients with non-seminomatous germ cell tumors who present with enlarging metastatic masses during appropriate systemic chemotherapy in the context of normalized serum markers. This is an infrequent event in the progression of testicular tumors, and is even less common in the case of ovarian germ cell tumors. The pathogenesis of GTS is not completely understood and diagnosis can only be made with certainty after complete pathologic examination. Although histologically benign, GTS may present an enveloping growth with aggressive local expansion, which can be related to substantial morbidity and mortality. Surgery is the only recommended treatment and early recognition of this syndrome is essential as it offers hope for curative resection and avoids the use of ineffective chemotherapy. The authors present a brief review of the literature, along with the case report of a 37-year-old woman presenting GTS with liver involvement who was successfully treated by debulking surgery followed by major liver resection. This report demonstrates that complete surgical resection results in excellent disease control. More importantly, it highlights that clinicians need to be aware of the possible development of GTS when monitoring their patients with non-seminomatous germ cell tumors. These patients require coordinated care between oncologist, gynecologists, and general surgeons to obtain the best possible outcomes.
    European journal of gynaecological oncology 09/2015; 36(4):473-476. DOI:10.12892/ejgo2639.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of investigation: To compare the therapeutic and side effects of using Californium252 (252Cf) neutron brachytherapy with neoadjuvant intra-arterial embolism chemotherapy in combination with surgery for treating Stage Ib2-IIb cervical cancers (CCs). Materials and methods: Thirty-two Stage Ib2-IIb CC patients were enrolled and randomly divided into two groups from January 2007 to April 2010 in the present Hospital. Prior to surgery within four weeks, a total of 17 cases were treated with 252Cf neutron brachytherapy (700-800 cGy doses at point A) once a week (Group A), and 15 cases were treated by neoadjuvant intra-arterial embolism chemotherapy using a combination of bleomycin, carboplatin, and cyclophosphamide twice (Group B). The clinical symptoms and signs, side effects, and relapse condition follow up until July 2013 were compared between the two groups for the perioperation. Results: Reductions in tumor mass and CR+PR were not significantly different between the groups before the surgery (p > 0.05). Abdominal pain and pelvic adhesions were significantly more severe in Group B (p < 0.05). There were no significant differences in surgical time, blood loss or the other side effects between Groups A and B (p > 0.05). The percentage of pelvic tumor recurrences in Group A was lower than that of the patients in Group B (11.8% vs 20.0%) although with no significant difference at present. No distant metastasis has been found in both two groups. Conclusion: Except for less abdominal pain and pelvic adhesions, 252Cf neutron brachytherapy has perioperative effects similar to those of neoadjuvant intra-arterial embolism chemotherapy.
    European journal of gynaecological oncology 09/2015; 36(4):442-446. DOI:10.12892/ejgo2667.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The purpose of this study was to identify the drug resistant role of miR-224 expression in cervical cancer. Materials and Methods: The expression of miR-224 pre- and post-paclitaxel treatment was determined by using stem-loop real-time reverse transcription polymerase chain reaction (RT-PCR). The authors exogenously upregulated miR-224 expression in SiHa cells using miRIDIAN miR-224 mimic transfection and observed its impact on paclitaxel sensitivity using Cytotoxicity assays. Results: MiR-224 was significantly downregulated with fold values at 2.130435 and 4.26087 under five and ten nM paclitaxel treatments, respectively. MiR-224 expression is markedly increased in SiHa cells after transfected with miRIDIAN miR-224 mimic. Exogenous miR-224 facilitates paclitaxel sensitivity in cervical cancer cells. The IC50 value was decreased in SiHa with overexpression of miR-224 compared with miRNA-negative control (p < 0.0001). Conclusion: The results suggests that miR-224 might serve as a predictor for paclitaxel response or a therapeutic target in cervical cancer therapy.
    European journal of gynaecological oncology 09/2015; 36(4):432-436. DOI:10.12892/ejgo2668.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Herein the authors report the first case of prophylactic bilateral salpingo-ovariectomy (BSO) in single port access laparoscopy (SEAL) with use of diode laser in a patient with BRCA1 mutation. As fimbria could be considered the site of origin for many serous carcinomas in BRCA mutation carriers, many studies are carried out to evaluate the possibility of preventing ovarian carcinoma with BSO. SEAL is a development of endoscopic surgery which further reduces invasiveness of surgical procedures. Diode laser presents a recognized precision for tissue cutting and coagulation and its use could be highly advantageous in SEAL surgery and in particular in such situations avoiding fallopian tube histology distortion and consequently improve the prognosis of BRCA carriers.
    European journal of gynaecological oncology 09/2015; 36(4):479-481. DOI:10.12892/ejgo2795.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To evaluate the outcome and adherence of 535 patients with cytological changes. Materials and methods: Study of 7519 smear tests harvested in 2007. Results: Of the 7,519 (100%) patients analyzed, 6,964 (92.6%) had cytology negative for intraepithelial lesion or malignancy, 535 (7.1%) abnormalities in epithelial cells, and 20 (0.3%) were unsatisfactory. Of these 535 (100%) patients, 511 (95.5%) were referred to the outpatient clinic and colposcopic exam submitted and 24 (4.5%) did not return to the clinic. The group participated in the ambulatory visits, 302 (59.1%) underwent colposcopy-guided biopsy, and the remaining 209 (40.9%) examinations were negative. Conclusion: The cytological examination remains the method of choice for cervical cancer screening. It includes low costs, is effective, and well-accepted. Early diagnosis minimises the cost of research. Universities have an important role in the training of health professionals and also in the development of research.
    European journal of gynaecological oncology 09/2015; 36(4):437-441. DOI:10.12892/ejgo2687.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The prognosis for breast cancer has been considered to be worsened by the coexistence of pregnancy. However, to date, significant controversy still exists regarding the pathological tumor features and prognosis of patients diagnosed with pregnancy-associated breast cancer (PABC). The aim of the present study was to analyze the different prognostic factors and outcome in PABC subset versus a non-PABC control group matched for age and year of diagnosis. Materials and methods: A total of 56 PABC cases were diagnosed from 1990 to 2008, for whom 73 non-PABC patients were identified. Pathological characteristics, immunohistochemical fea- tures, and differences in overall and disease-free survival were compared between both groups. Results: Compared to non-PABC controls, PABC patients presented more advanced disease (31% vs 13%, p = 0.024) and greater lymph node involvement (53% vs 34%, p = 0.034). Pathological and tumor features tended to present poorer prognostic factors in the PABC subset. Survival was poorer in the PABC patients (five-year DFS 68% in PABC vs 86% in non-PABC, p = 0.12). However, analysing survival adjusted for stage and age, the authors did not find significant differences between both groups. Conclusions: PABC patients tended to be diagnosed in advanced breast disease and presented tumors with adverse pathological prognostic factors. While the authors found a poorer outcome in PABC group, no significant differences were observed with stage-matched analysis. The present results may suggest that the poorer prognosis observed within PABC women could not be due to pregnancy itself, but with a delay in diagnosis and tumor subtype pathological features.
    European journal of gynaecological oncology 09/2015; 36(4):420-423. DOI:10.12892/ejgo2632.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Despite recent advances in the treatment of recurrent ovarian cancer, little evidence exists describing the benefit of third- line chemotherapy. The present authors previously reported that the treatment-free interval (TFI) after second-line chemotherapy may predict a survival benefit of third-line chemotherapy, however the length of TFI was uncertain due to limited cases. In this study, the authors evaluated the length of TFI, which is correlated with the effectiveness of third-line chemotherapy and a prognostic factor of third-line chemotherapy. Materials and methods: The authors reviewed the medical records of 85 women with recurrent ovarian cancer who received third-line chemotherapy after a paclitaxel/carboplatin (PC) regimen as first-line chemotherapy. Results: The response rate [complete response (CR) + partial response (PR)] and clinical benefit rate [(CBR): CR + PR + stable disease (SD)] during the TFI after second-line chemotherapy for 0-3 months, 3-6 months, and 6-12 months and ≥ 12 months were 9.8%, 0%, 0%, 43.8% and 15.7%, 50%, 66.7%, and 93.8%, respectively. The median overall survival (OS) from the onset of third-line chemotherapy was longer for TFI ≥ 3 months than for TFI 0-3 months (795 days vs. 281 days, p < 0.001). Finally, according to univariate (HR = 0.256; p < 0.001) and multivariate (HR = 0.264; p < 0.001) analyses, TFI was the independent significant prognostic factor for OS. Conclusions: TFI less than three months after second-line chemotherapy may predict little survival benefit of third-line chemotherapy.
    European journal of gynaecological oncology 09/2015; 36(4):424-427. DOI:10.12892/ejgo2646.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To investigate the expression of PI3K-p110α, pAkt, PTEN, the signaling molecules from PI3K/Akt signaling pathway, DJ-1, an oncoprotein and HSP90a, a molecular chaperone, and their correlation in uterine cervical neoplasia, in order to elucidate their role in cervical carcinogenesis. Materials and methods: Using immunohistochemistry, the authors analyzed the expression of PI3K-p110α, pAkt, PTEN, DJ-1 and HSP90α, and their correlation in ten normal tissues, cervical intraepithelial neoplasia (CIN) including 30 CIN1 and 31 CIN3, and 33 cases of invasive squamous cell carcinoma (SCC). Results: The expression of all proteins significantly increased in CIN3 compared to CIN1, and only the expression of PI3K-p110α significantly increased in invasive SCC compared to CIN3. There was a significant positive correlation between the expression of PI3K-p110α and DJ-1, as well as PI3K-p110α and pAkt in CIN3 and invasive SCC. Conclusion: Overexpression of PI3K-p110α is associated with progression of uterine cervical neoplasia, and the expression of pAkt and DJ-1 is positively correlated with PI3K-p110α expression in this process.
    European journal of gynaecological oncology 09/2015; 36(4):389-393. DOI:10.12892/ejgo2591.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To describe the prevention, diagnosis, and treatment of cervical cancer precursor lesions at the Xingu Indigenous Park (PIX) from 2005 to 2006. Materials and methods: Observational, transversal study. The research sample consisted of 503 sexually active women aged 12 years and older. The research was performed in three stages: screening, colposcopy, and surgical treatment by large loop excision of the transformation zone. Results: The cytopathological screening coverage was of 99.6%. The rate of cytologic atypia was 11.7%. Together, low-grade squamous intraepithelial lesions (LSILs) and high-grade squamous intraepithelial lesions (HSILs) were observed in 4.6% of the women. The cytological examination returned a sensitivity of 54%, specificity of 97%, a positive predictive value of 88%, and a negative predictive value of 83%. In the anatomopathological examinations of biopsies, the rate of HSILs was 30.2%. The sensitivity of the anatomopathological examination of biopsies was 72.2%, the specificity was 100%, the positive predictive value was 100%, and the negative predictive value was 44.4%. Conclusions: Viable strategies for preventing, diagnosing, and treating cervical cancer precursor lesions in women from the PIX include increasing annual coverage of cytopathological examinations, early detection of cervical intraepithelial lesions, and treatment and follow-up of detected cases.
    European journal of gynaecological oncology 09/2015; 36(4):376-382. DOI:10.12892/ejgo2649.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of investigation: This study aimed to assess the role of omentectomy in the surgical therapy of endometrial cancer. MATERI- ALS AND METHODS: A retrospective study was performed in 98 patients who were pathologically diagnosed with endometrial cancer and had initially undergone surgical therapy at the present institution. This study analyzed the relationship between omental metastasis and clinicopathological factors. Results: Omental metastasis was detected in nine patients (9%). On univariate analysis, significant number of omental metastatic lesions were detected in few cases by positive peritoneal cytology, adnexal metastasis, gross dissemination, and lymphovascular space involvement. On multivariate analysis, adnexal metastasis were a significant risk factor. The sensitivity of the spe- cial histological type and the specificity of the macroscopic peritoneal dissemination and adnexal metastasis were all high. Conclusion: Omentectomy plays a significant role in determining the exact surgical staging in cases with non-endometrioid cancer, adnexal metas- tasis, and macroscopic peritoneal dissemination.
    European journal of gynaecological oncology 09/2015; 36(4):397-401. DOI:10.12892/ejgo2657.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate the serum concentrations of anti-heat shock protein 20 (anti-Hsp20) antibodies in women with ovarian cancer at different clinical stages, and the relationship between these concentrations and tumor progression. Materials and methods: Blood samples were obtained from 72 patients undergoing surgery for ovarian cancer, 21 women with ovarian carcinoid, and 42 healthy women. Anti-Hsp20 antibody concentrations were determined by enzyme-linked immunosorbent assay. Results: Mean anti-Hsp20 antibody concentrations were significantly lower in patients with ovarian cancer than in the control group. The anti-Hsp20 antibody concentrations were negatively correlated with ovarian cancer malignancy. Conclusions: The present findings suggest that anti-Hsp20 antibodies may play a protective role against ovarian cancer progression, and that anti-Hsp20 antibodies may be a new index for the early diagnosis and treatment of ovarian cancer.
    European journal of gynaecological oncology 09/2015; 36(4):394-396. DOI:10.12892/ejgo2623.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Paraneoplastic neurological syndromes (PNS) are immune-mediated, subacute, and progressive syndromes caused by remote effects of malignant tumours rather than the direct infiltration of tumours. The most common maladies related to PNS are small cell lung cancer, breast and ovarian cancer, and Hodgkin's lymphoma. Diagnoses of PNS frequently precede tumour diagnoses because the primary tumour is often occult. It is difficult for clinicians to recognise PNS, because there are various neurological symptoms and signs in the patient but few abnormal results of the examinations. The examination of paraneoplastic panels (cerebrospinal fluid (CSF) and serum) is useful in the diagnosis of PNS, but the false negatives should be considered. Due to the severe neurological morbidity and mortality caused by PNS, early diagnoses are important to allow for time to treat the underlying tumour and to obtain functional improvement. It is worth noting that regular re-examination and follow-up are crucial for reducing the rates of misdiagnosis and missed diagnosis of PNS.
    European journal of gynaecological oncology 09/2015; 36(4):485-487. DOI:10.12892/ejgo2682.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The purpose of this study was to evaluate serum concentrations of human epididymis protein 4 (HE4) and cancer antigen 125 (CA 125) in healthy women and their pregnant counterparts to determine the influence of pregnancy on these biomarkers. Materials and methods: Serum concentrations of CA 125 and HE4 were measured in 27 healthy non-pregnant women and 26 healthy pregnant women in the first and second trimesters. Results: Higher concentration of CA 125 was found in pregnants than in non-pregnant women (p = 0.002). There was no difference in CA 125 concentrations between first and second trimesters (p = 0.13). Serum HE4 concentration was not different in pregnant group compared to non-pregnant women (p = 0.510). Likewise, no difference was found in HE4 levels between the trimesters (p = 0.485). There was a positive correlation between increasing parity and CA 125 (p = 0.023), but not HE4 (p = 1.0). Conclusion: HE4 serum biomarker is unaffected by pregnancy status and may be useful for evaluation of doubtful pelvic masses in pregnancy. Contrarily, increased serum levels of CA 125 could yield increased number of false-positive results.
    European journal of gynaecological oncology 09/2015; 36(4):406-409. DOI:10.12892/ejgo2672.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To explore the effect of LRIG3 in the development of cervical squamous cell carcinoma. Materials and methods: LRIG3 and epidermal growth factor receptor (EFGR) expressions were detected by immunohistochemistry. Western blot method was used to detect LRIG3 and EGFR protein expression at different time points. MTT, flow cytometry, and transwell chamber were adopted to examine the proliferation, apoptosis, and strength of invasion of Hela229 cell respectively. Results: During the process of normal cervix deteriorating into CIN and CSCC, LRIG3 expression gradually decreased, while EGFR increased. After the transfection of LRIG3 ASODN into cells, the amount of LRIG3 expression and the cell apoptosis rate both decreased gradually, EGFR protein expression and cell proliferation rate both increased (p < 0.05), other groups remained unchanged (p > 0.05). The cell migration ability in LRIG3 ASODN transfection group was stronger than that of other groups (p < 0.05). Conclusion: LRIG3 plays an important role in Hela229 cell proliferation, apoptosis, and invasiveness.
    European journal of gynaecological oncology 09/2015; 36(4):414-419. DOI:10.12892/ejgo2686.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: MicroRNA-451 has been proved to be downregulated in many human malignancies and correlated with tumor progression. However, its expression and clinical significance in epithelial ovarian cancer (EOC) is still unclear. The aim of this study was to explore the effects of miR-451 in EOC tumorigenesis and development. Materials and methods: The expression levels of miR-451 were quantified by qRT-PCR in 115 EOC and 34 normal ovarian tissues, and correlated with clinicopathological factors and prognosis. MTT, flow cytometric assay, and transwell invasion assay were used to test the proliferation, apoptosis, and invasion of SKOV-3 EOC cells transfected with miR-451 mimics or negative control (NC) RNA-oligonucleotides. Results: MiR-451 expression was significantly downregulated in EOC compared with normal ovarian tissues. Low level of miR-451 was associated with advanced FIGO stage (p = 0.005), higher serum CA125 expression level (p = 0.005), and lymph node metastasis (p = 0.002). Multivariate Cox regression analysis identified decreased miR-451 expression as an independent factor predicting poor prognosis for EOC patients. In addition, transfection of miR-451 mimics in SKOV-3 was able to reduce cell proliferation, promote cell apoptosis, and inhibit cell invasion. Conclusions: miR-451 may act not only as a novel diagnostic and prognostic marker, but also as a potential target for molecular therapy of EOC.
    European journal of gynaecological oncology 09/2015; 36(4):463-468. DOI:10.12892/ejgo2624.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Endometrial clear cell carcinoma (CCC) is a rare entity and only accounts for 1-6% of all endometrial cancers. CCC is considered an aggressive subtype of endometrial cancer with worse prognosis compared with type I cancer and more frequent relapses at distant and extrapelvic sites. These characteristics require specific treatment modalities, but rarity of the disease does not allow to identify evidence based indications for therapies. Objective of the present study is to analyse a series of cases treated in a multicentre Italian setting. Materials and methods: Sixty-five endometrial CCC were treated in the period 1990-2010 in the participating institutions. Slides of the pathological specimens were reviewed by a single pathologist of each institution and debatable cases were collegially reviewed. Clinical records were collected by a common database. Demographic, surgical pathological, and follow-up data were registered. Results: All patients received primary surgery. Stage of disease according FIGO 2009 was as follow: l a: 16.9%, lb: 35.4%, 2: 9.2%, 3a: 9.2%, 3b: 3.1%, 3c: 16.9%, 4a: 3.1%, and 4b: 6.1%. Adjuvant post-operative treatment was adopted in 53.8% of cases. A relapse was detected in 29.2% of cases with a majority of extrapelvic sites (68.4%). Five-year survival rate was significantly related to stage of disease with an excellent prognosis for Stage Ia e lb disease with a complete staging. In these cases adjuvant treatment does not show significant improvement of survival. Relapsed cases show a response rate to treatment in 26% of cases (predominantly chemotherapy). Conclusion: CCC requires extensive surgical staging. Stage I disease completely staged does not require adjuvant therapy. More advanced stages require adjuvant chemotherapy.
    European journal of gynaecological oncology 09/2015; 36(4):428-431. DOI:10.12892/ejgo3097.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of investigation: HE4 (human epididymis protein 4) is suggested to be used as a potential new biomarker to identify ovarian malignancies from benign adnexal masses. The aim of this study was to evaluate HE4, in comparison with CA125 and Risk of Ovarian Malignancy Algorithm (ROMA) index in benign gynecological diseases and ovarian cancer, and additionally to determine the reference range for HE4 in healthy Turkish women. Materials and methods: CA125 and HE4 serum levels were determined in 96 patients with benign gynecological diseases, 47 patients with ovarian cancer and 106 healthy women using a specific analyzer. CA125 and HE4 cut-offs were 35 U/ml and 70 pmol/L, respectively. Results: HE4 had significantly higher concentrations in ovarian cancer than benign gynecologic disorders (p < 0.005). Tumor marker sensitivity in ovarian cancer was 78% for HE4, 63% for CA125, and 88% for ROMA index at 95% specificity. A significantly higher area under the Receiver operator characteristic (ROC) curve was obtained with HE4 and ROMA index than CA125 in the differential diagnosis of benign gynecological diseases versus ovarian cancer (0.929, 0.955, and 0.781, respectively). Reference limits for serum HE4 in healthy Turkish women was determined as 28.9-62.4 pmol/L for pre-menopausal and 23.7-152.4 pmol/L for postmenopausal women. Conclusions: In the diagnosis of ovarian cancer, HE4 had higher sensitivity, as a single tumor marker. The sensitivity of HE4 and ROMA index in postmenopausal women was higher than premenopausal women for detecting ovarian cancer.
    European journal of gynaecological oncology 09/2015; 36(4):457-462. DOI:10.12892/ejgo2714.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the outcome of vaginal intraepithelial neoplasia (VaIN) treatment with CO2 laser vaporization in terms of local recurrence and progression to vaginal carcinoma. Additionally, the authors investigated the predictive factors for first recurrence. Materials and methods: The medical records of all patients treated for VaIN with CO2 laser vaporization at Sant'Anna Hospital in Turin (1995-2012), were retrospectively reviewed. A univariate logistic model was applied to evaluate selected clinical features as predictive factors for recurrence. A multivariate logistic regression analysis was then carried out including significant risk factors after univariate analysis (p < 0.05). Results: The analysis included 285 out of 302 patients. Seventy-one (25%) women relapsed; of these 24 VaIN 1 (22%), 37 VaIN 2 (27%), and ten VaIN 3 (26%). The median time to the first recurrence was 5.2 months (1.4-127.8) for VaIN 1, 6.6 months (1-85.2) for VaIN 2, and 3.6 months (1.2-62) for VaIN 3. Sixty-one out of 71 patients were retreated with CO2 laser vaporization. At the last follow-up visit, 273 (96%) women were free from VaIN. No patients progressed to vaginal carcinoma. The multivariate model showed a higher risk of VaIN recurrence in the case of previous hysterectomy (HR 3.3, 95% CI 1.7-6.3, p < 0.001) and concomitant H-SIL on the Pap smear (HR 1.9, 95% CI 1.2-3.1, p = 0.008). Conclusion: CO2 laser vaporization is an effective low impact treatment for VaIN. Despite this, VaIN recur, in particular in cases of previous hysterectomy and concomitant H-SIL on the Pap smear. An intensive follow-up is proposed for women with a high risk of VaIN relapse.
    European journal of gynaecological oncology 09/2015; 36(4):383-388. DOI:10.12892/ejgo3063.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Squamous cell carcinoma of the Bartholin's glands is a very rare form of vulvar neoplasm. This case presents a 46-year-old female diagnosed with advanced primary squamous cell cancer of the Bartholin glands that has proven positive for human papillomavirus (HPV). The patient was treated with a wide excision of the tumor, an ipsilateral lymphadenectomy, and an adjuvant chemotherapy and irradiation. After two years of follow-up the patient remains in remission.
    European journal of gynaecological oncology 09/2015; 36(4):482-484. DOI:10.12892/ejgo2654.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Case: A 58-year old woman presented with microcalcifications in her left breast. A biopsy showed a low-grade ductal carcinoma in situ. A tumorectomy was performed using a harpoon-shaped guide wire to remove the entire lesion. No additional therapy was given. Six months later during follow-up the mammography revealed that the distal end of the guide wire was still present in the left breast. Conclusion: When performing a tumorectomy using a guide wire, the completeness of the wire should be checked during surgery. Additionally cutting of the wire can be prevented by using a scalpel instead of scissors during surgery.
    European journal of gynaecological oncology 09/2015; 36(4):477-478. DOI:10.12892/ejgo2642.2015